17-31232117-C-G
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM1BP4BP6BS2_Supporting
The NM_001042492.3(NF1):c.3242C>G(p.Ala1081Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000135 in 1,556,184 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A1081P) has been classified as Uncertain significance.
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Publications
- neurofibromatosis type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
- Moyamoya diseaseInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000746 AC: 1AN: 133996Hom.: 0 Cov.: 28 show subpopulations
GnomAD2 exomes AF: 0.0000201 AC: 5AN: 248840 AF XY: 0.0000223 show subpopulations
GnomAD4 exome AF: 0.0000141 AC: 20AN: 1422188Hom.: 0 Cov.: 31 AF XY: 0.00000848 AC XY: 6AN XY: 707840 show subpopulations
GnomAD4 genome AF: 0.00000746 AC: 1AN: 133996Hom.: 0 Cov.: 28 AF XY: 0.00 AC XY: 0AN XY: 63434 show subpopulations
ClinVar
Submissions by phenotype
not specified Uncertain:1
DNA sequence analysis of the NF1 gene demonstrated a sequence change, c.3242C>G, in exon 25 that results in an amino acid change, p.Ala1081Gly. This sequence change does not appear to have been previously described in patients with NF1-related disorders and has been described in the gnomAD database with a low population frequency of 0.0020% (dbSNP rs769941435). The p.Ala1081Gly change affects a moderately conserved amino acid residue located in a domain of the NF1 protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Ala1081Gly substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Ala1081Gly change remains unknown at this time. -
Neurofibromatosis, type 1;C0349639:Juvenile myelomonocytic leukemia;C0553586:Café-au-lait macules with pulmonary stenosis;C1834235:Neurofibromatosis, familial spinal;C2931482:Neurofibromatosis-Noonan syndrome Uncertain:1
- -
not provided Uncertain:1
- -
Neurofibromatosis, type 1 Benign:1
- -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at